JP Morgan Gives Cooper (NYSE:COO) a Lower Rating. Drops its Overweight Rating


Cooper (NYSE:COO) Receives a Downgrade

JP Morgan has given Cooper (NYSE:COO) shares a new Neutral rating in an analyst note revealed to clients on Friday, 4 December. This was a ratings cut from the past Overweight rating.

From a total of 10 analysts covering Cooper (NYSE:COO) stock, 10 rate it a ”Buy”, 0 a “Sell”, and 4 a ”Hold”. This means that 71% of the ratings are positive. The highest target price is $205 while the lowest target price is $136. The mean of all analyst targets is $178.1 with a 44.37% above today’s ($130.01) stock price. Cooper was the topic of 9 analyst reports since August 26, 2015 according to the firm StockzIntelligence Inc. Wells Fargo downgraded shares on November 17 to “Market Perform” rating. Piper Jaffray maintained COO stock in a recent report from September 4 with “Buy” rating. Finally, KeyBanc Capital Markets upgraded the stock to “Sector Weight” rating in a report issued on an August 26.

Approximately 2.59 million shares of stock traded hands or 478.46% up from the average. Cooper Companies Inc (NYSE:COO) has declined 20.20% since May 1, 2015 and is downtrending. It has underperformed by 17.41% the S&P500.

The Cooper Companies, Inc. , is a global medical device company. The company has a market cap of $6.95 billion. The Firm operates through two business units, CooperVision, Inc. (CVI) and CooperSurgical, Inc. (CSI). It has 32.37 P/E ratio. CooperVision is a global maker providing products for contact lens wearers.

According to Zacks Investment Research, “The Cooper Companies, Inc., through its principal subsidiaries, develops, manufactures and markets healthcare products. CooperVision markets a range of contact lenses to correct visual defects, specializing in toric lenses that correct astigmatism. The company also markets conventional toric and spherical lenses and lenses for patients with more complex vision disorders. CooperSurgical markets diagnostic products, surgical instruments and accessories to the women’s healthcare market.” Get a free copy of the Zacks research report on Cooper Companies Inc (COO).